ES2094974T3 - Derivados de 17-aril- y 17-heterociclil-14beta-5alfa-androstano, androsteno y androstadieno, activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos. - Google Patents

Derivados de 17-aril- y 17-heterociclil-14beta-5alfa-androstano, androsteno y androstadieno, activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.

Info

Publication number
ES2094974T3
ES2094974T3 ES93112408T ES93112408T ES2094974T3 ES 2094974 T3 ES2094974 T3 ES 2094974T3 ES 93112408 T ES93112408 T ES 93112408T ES 93112408 T ES93112408 T ES 93112408T ES 2094974 T3 ES2094974 T3 ES 2094974T3
Authority
ES
Spain
Prior art keywords
preparation
pharmaceutical compositions
derivatives
androstadieno
heterociclil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93112408T
Other languages
English (en)
Inventor
Piero Melloni
Luigi Bernardi
Mara Ferrandi
Marco Frigerio
Marina Mauro
Luisa Quadri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2094974T3 publication Critical patent/ES2094974T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DERIVADOS DE 17-ARIL Y 17-HETEROCICLIL-5(ALFA),14(BETA)-ANDROSTANO Y ANDROSTENO Y ANDROSTADIENO DE LA FORMULA (I): EN DONDE: LOS SIMBOLOS DE LINEA ONDULADA, LINEA RECTA CON UNA DE RAYAS SUPERPUESTA, Y, R Y R1 TIENEN EL SIGNIFICADO INDICADO EN LA DESCRIPCION, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ES93112408T 1992-09-29 1993-08-03 Derivados de 17-aril- y 17-heterociclil-14beta-5alfa-androstano, androsteno y androstadieno, activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos. Expired - Lifetime ES2094974T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232681A DE4232681C2 (de) 1992-09-29 1992-09-29 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung

Publications (1)

Publication Number Publication Date
ES2094974T3 true ES2094974T3 (es) 1997-02-01

Family

ID=6469164

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93112408T Expired - Lifetime ES2094974T3 (es) 1992-09-29 1993-08-03 Derivados de 17-aril- y 17-heterociclil-14beta-5alfa-androstano, androsteno y androstadieno, activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.

Country Status (12)

Country Link
US (2) US5556846A (es)
EP (1) EP0590271B1 (es)
JP (1) JPH06192287A (es)
KR (1) KR940007054A (es)
AT (1) ATE145649T1 (es)
CA (1) CA2106916A1 (es)
DE (2) DE4232681C2 (es)
DK (1) DK0590271T3 (es)
ES (1) ES2094974T3 (es)
GR (1) GR3021789T3 (es)
HK (1) HK1005880A1 (es)
ZA (1) ZA937112B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1279386B1 (it) * 1994-11-07 1997-12-10 Sigma Tau Ind Farmaceuti 1,5 derivati di 7a-metilperidroinden-3a-oli, attivi sul sistema cardiovascolare, procedimenti per la loro preparazione e composizioni
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009137337A1 (en) * 2008-05-05 2009-11-12 The Scripps Research Institute STEREOSELECTIVE SYNTHESIS OF 17-α -AND 17-β -ARYL STEROIDAL COMPOUNDS
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
JP5738267B2 (ja) 2009-03-23 2015-06-24 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ タンパク尿、糸球体硬化、及び腎不全の治療に有用な５−β，１４−β−アンドロスタン誘導体
CN102822190B (zh) * 2009-11-13 2016-03-30 拓凯制药公司 哺乳动物的类固醇代谢物
PT2766380T (pt) 2011-10-14 2019-07-29 Sage Therapeutics Inc Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
RS61733B1 (sr) 2013-07-19 2021-05-31 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotrebe
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
EP3488852B1 (en) 2013-08-23 2020-10-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA2964898A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MX2021004492A (es) 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
ES2965214T3 (es) 2016-07-11 2024-04-11 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C17, C20 y C21 y sus procedimientos de utilización
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405127A (en) * 1965-07-13 1968-10-08 Sterling Drug Inc 12, 17-dioxygenated steroids
DE1768800C3 (de) * 1968-07-02 1978-07-06 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 14 ß- Hydroxy-3oxo-5 a-card-20(22)- enoliden
DE2614046C2 (de) * 1976-04-01 1984-08-02 Boehringer Mannheim Gmbh, 6800 Mannheim Neue 17α-Hydroxy-Cardenolid-Glykoside, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
IT1250410B (it) * 1991-02-14 1995-04-07 Simes Composti steroidei attivi sul sistema cardiovascolare
DE4232638C2 (de) * 1992-09-29 1994-11-17 Sigma Tau Ind Farmaceuti 17-Phenyl-5beta-14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
DE4232681A1 (de) 1994-03-31
GR3021789T3 (en) 1997-02-28
KR940007054A (ko) 1994-04-26
DE69306212T2 (de) 1997-04-24
ZA937112B (en) 1995-07-25
US5556846A (en) 1996-09-17
JPH06192287A (ja) 1994-07-12
EP0590271A3 (en) 1994-07-06
ATE145649T1 (de) 1996-12-15
HK1005880A1 (en) 1999-01-29
US5721227A (en) 1998-02-24
EP0590271B1 (en) 1996-11-27
EP0590271A2 (en) 1994-04-06
DK0590271T3 (da) 1996-12-16
CA2106916A1 (en) 1994-03-30
DE69306212D1 (de) 1997-01-09
DE4232681C2 (de) 1994-11-24

Similar Documents

Publication Publication Date Title
ES2094974T3 (es) Derivados de 17-aril- y 17-heterociclil-14beta-5alfa-androstano, androsteno y androstadieno, activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
ES2095432T3 (es) Derivados de 2,4-tiazolidin-diona, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AU3709789A (en) Benzofused heterocyclics used as pharmaceuticals
MX9203385A (es) Derivados de taxol y composiciones farmaceuticas que los contienen.
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
PT97065A (pt) Processo para a preparacao de 1,4,7,1o-tetraazaciclodecano-butiltrois e de composicoes farmaceuticas que os contem
ES2097297T3 (es) Isoquinolein-5-il-sulfonamidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
BR1100987A (pt) Composto, composição farmacêutica da matéria, e, composição veterinária
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
DE69521672D1 (de) Topisch verabreichbare zinkphthalocyaninhaltige Mittel
PT92146A (pt) Processo para a preparacao do inibidor de glicosidade salbostatina e de composicoes farmaceuticas que a contem
GR3024686T3 (en) Novel guinolone and naphthyridone derivatives.
DE59300171D1 (de) Organopolysiloxanzusammensetzung.
ES2111871T3 (es) Nuevos derivados de aminoacidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2104808T3 (es) Derivados de 4,13-dioxabiciclo(8.2.1.)tridecenona, procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
MX9200731A (es) Compuestos de hidrazona, procedimientos para su prcompuestos de hidrazona, procedimientos para su preparacion, compuestos intermedios utiles para su oeparacion, compuestos intermedios utiles para suobtencion y composiciones pesticidas que contienena btencion y composiciones pesticidas que contienenalos mismos. los mismos.
MX191084B (es) Composiciones inhibidoras de trasnferencia de colorante que contienenagente tensioactivo.
ES2100396T3 (es) Derivados de 17-(3-furil)- y 17-(4-piridazinil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que los contienen.
ATE96356T1 (de) Flussmittelzusammensetzung.
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
ES2095431T3 (es) N-(isoquinolein-5-il)-sulfonil-azacicloalcanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO923266L (no) Heksahydrobenzo(f)quinolinoner
IT1263892B (it) Composti piperidin-triazinici atti all'impiego come stabilizzanti per materiali organici
ES2104295T3 (es) Derivados ciclopeptidicos de la angiopeptina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR001352A1 (es) Bencenofulfonifureas y bencenosulfoniltioureas sustituidas, procedimiento para sus preparaciones, sus usos para producir preprarados farmaceuticos y los medicamentos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590271

Country of ref document: ES